Albertsons Companies, Inc.

OMAHA, Neb.--(BUSINESS WIRE)---- $ACIW #AWS--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, and Cognizant (NASDAQ: CTSH), a leading AI builder and technology services provider, today announced the results of joint performance testing of BASE24-eps, a foundational component of ACI's card acquiring and issuing solutions, on AWS. Under simulated point-of-sale load, BASE24-eps sustained more than double its target transaction load for 30 minutes with no failed transactions. Acr.

AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered ACI-24 for prodromal Alzheimer's, triggering a $12M milestone and showing antibody responses at all dose levels. Brain-penetrant NLRP3 inhibitor ACI-19764 advances, with phase 1/1b initial data at the end of 2026 and final data in the 1st half of 2027, targeting neuroinflammatory and metabolic disorders.

OMAHA, Neb.--(BUSINESS WIRE)---- $ACIW #Banking--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced that Solaris, Europe's leading embedded finance platform, has gone live on schedule on ACI Connetic, ACI's unified cloud-native platform for intelligent payments orchestration. The milestone marks the successful completion of the first phase of Solaris' payments modernization initiative. By consolidating its SEPA Instant payments infrastructure onto ACI Connetic, Sola.

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision.